Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran vs Enoxaparin for Portal Vein Thrombosis in Cirrhosis
NCT06818279Phase 3Not yet recruiting
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dabigatran in portal vein thrombosis (PVT) (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Proportion of patients achieving complete recanalization of Portal Vein Thrombosis at 6 months. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
dabigatran
03
Conditions
portal vein thrombosis (PVT)
Beyond the preview
Go deeper on NCT06818279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06818279.